Cover Image
市場調查報告書

INSYS Therapeutics, Inc.:產品平台分析

INSYS Therapeutics, Inc. - Product Pipeline Review - 2016

出版商 Global Markets Direct 商品編碼 224713
出版日期 內容資訊 英文 45 Pages
訂單完成後即時交付
價格
Back to Top
INSYS Therapeutics, Inc.:產品平台分析 INSYS Therapeutics, Inc. - Product Pipeline Review - 2016
出版日期: 2016年04月20日 內容資訊: 英文 45 Pages
簡介

INSYS Therapeutics, Inc.致力於研發、開發、銷售對應化療誘發性噁心嘔吐(CINV)的創新產品的藥物。尤其集中性地進行適合化療的副作用的治療藥,及疼痛管理、中樞神經系統(CNS)治療方法的開發。同時也發展吸引式及室溫膠囊/糖漿式的屈大麻酚的開發。該公司還打算開發使用創新的藥物遞送系統,現有的醫藥品的更有效利用方法。

本報告提供美國的生物醫藥品企業,INSYS Therapeutics, Inc.(INSYS Therapeutics)的醫藥品的研究開發的進展相關分析,該公司的產品平台結構,及臨床實驗的整體進展,主要開發中產品簡介與開發情形,該公司簡介與最新趨勢等。

目錄

INSYS Therapeutics, Inc.:現狀

  • 企業概要
  • 主要資訊
  • 主要資料

研究開發(R&D)概況

  • 主要的治療領域

開發平台、檢討

  • 各開發階段的開發中產品
  • 單劑治療藥
  • 聯合治療模式

開發中產品的概要

  • 最後階段的開發中產品
    • 登記前的產品/聯合治療模式
    • 第Ⅲ相有的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段產品/並用治療模式
    • 第一階段產品/並用治療模式
  • 初期階段的開發中產品
    • 臨床實驗前產品/並用治療模式

藥物簡介

  • 屈大麻酚
    • 產品概要
    • 作用機制
    • 研究開發(R&D)的發展
  • buprenorphine hydrochloride
  • Cannabidiol
  • (buprenorphine hydrochloride + naloxone hydrochloride)
  • naloxone hydrochloride
  • ondansetron hydrochloride
  • Paclitaxel
  • cetirizine hydrochloride + cromolyn sodium
  • diclofenac sodium
  • ketorolac tromethamine
  • sildenafil citrate

開發平台分析

  • 各標的
  • 各投藥法
  • 各分子類型
  • 各作用機制

開發中產品的最新趨勢

開發暫停的產品

開發中止的產品

  • 開發中止的產品簡介
    • 以腫瘤學的間皮素為標的之單株抗體複合體

企業的聲明

公司所在地及子公司

附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC08027CDB

Summary

Global Markets Direct's, 'INSYS Therapeutics, Inc. - Product Pipeline Review - 2016', provides an overview of the INSYS Therapeutics, Inc.'s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by INSYS Therapeutics, Inc., complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of INSYS Therapeutics, Inc.
  • The report provides overview of INSYS Therapeutics, Inc. including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses INSYS Therapeutics, Inc.'s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features INSYS Therapeutics, Inc.'s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate INSYS Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for INSYS Therapeutics, Inc.
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding INSYS Therapeutics, Inc.'s pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • INSYS Therapeutics, Inc. Snapshot
    • INSYS Therapeutics, Inc. Overview
    • Key Information
    • Key Facts
  • INSYS Therapeutics, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • INSYS Therapeutics, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Combination Treatment Modalities
  • INSYS Therapeutics, Inc. - Pipeline Products Glance
    • INSYS Therapeutics, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • INSYS Therapeutics, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • INSYS Therapeutics, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • INSYS Therapeutics, Inc. - Drug Profiles
    • dronabinol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • buprenorphine hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Cannabidiol
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • (buprenorphine hydrochloride + naloxone hydrochloride)
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • naloxone hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ondansetron hydrochloride
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • paclitaxel
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cetirizine hydrochloride + cromolyn sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • diclofenac sodium
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ketorolac tromethamine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • sildenafil citrate
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • INSYS Therapeutics, Inc. - Pipeline Analysis
    • INSYS Therapeutics, Inc. - Pipeline Products by Target
    • INSYS Therapeutics, Inc. - Pipeline Products by Route of Administration
    • INSYS Therapeutics, Inc. - Pipeline Products by Molecule Type
    • INSYS Therapeutics, Inc. - Pipeline Products by Mechanism of Action
  • INSYS Therapeutics, Inc. - Recent Pipeline Updates
  • INSYS Therapeutics, Inc. - Dormant Projects
  • INSYS Therapeutics, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • Monoclonal Antibody Conjugate to Target Mesothelin for Oncology
  • INSYS Therapeutics, Inc. - Company Statement
  • INSYS Therapeutics, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • INSYS Therapeutics, Inc., Key Information
  • INSYS Therapeutics, Inc., Key Facts
  • INSYS Therapeutics, Inc. - Pipeline by Indication, 2016
  • INSYS Therapeutics, Inc. - Pipeline by Stage of Development, 2016
  • INSYS Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • INSYS Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016
  • INSYS Therapeutics, Inc. - Pre-Registration, 2016
  • INSYS Therapeutics, Inc. - Phase III, 2016
  • INSYS Therapeutics, Inc. - Phase II, 2016
  • INSYS Therapeutics, Inc. - Phase I, 2016
  • INSYS Therapeutics, Inc. - Preclinical, 2016
  • INSYS Therapeutics, Inc. - Pipeline by Target, 2016
  • INSYS Therapeutics, Inc. - Pipeline by Route of Administration, 2016
  • INSYS Therapeutics, Inc. - Pipeline by Molecule Type, 2016
  • INSYS Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2016
  • INSYS Therapeutics, Inc. - Recent Pipeline Updates, 2016
  • INSYS Therapeutics, Inc. - Dormant Developmental Projects,2016
  • INSYS Therapeutics, Inc. - Discontinued Pipeline Products, 2016
  • INSYS Therapeutics, Inc., Other Locations
  • INSYS Therapeutics, Inc., Subsidiaries

List of Figures

  • INSYS Therapeutics, Inc. - Pipeline by Top 10 Indication, 2016
  • INSYS Therapeutics, Inc. - Pipeline by Stage of Development, 2016
  • INSYS Therapeutics, Inc. - Monotherapy Products in Pipeline, 2016
  • INSYS Therapeutics, Inc. - Combination Treatment Modalities in Pipeline, 2016
  • INSYS Therapeutics, Inc. - Pipeline by Top 10 Target, 2016
  • INSYS Therapeutics, Inc. - Pipeline by Route of Administration, 2016
  • INSYS Therapeutics, Inc. - Pipeline by Molecule Type, 2016
  • INSYS Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2016
Back to Top